During Wednesday’s trading session, shares of a global pharmaceutical company providing access to affordable and innovative medicines are in focus on the stock exchanges. The increased attention comes as the company is set to turn ex-dividend tomorrow, i.e., 10th July. All other relevant details can be found below.
With a market cap of Rs. 1.06 lakh crores, at 01:33 p.m., the shares of Dr. Reddy’s Laboratories Limited were trading in the red at Rs. 1,272.4 on BSE, down by nearly 1 percent, as against its previous closing price of Rs. 1,283.9. The stock has delivered negative returns of around 3.4 percent in one year, and has fallen by over 3 percent in the last one month.
What’s the News
The company has declared a Final dividend of Rs. 8 per share, equating to an 800 percent payout as compared to the face value of Rs. 1 each for the financial year ended 31st March 2025. The ex-dividend date has been fixed as 10th July 2025. In addition, Dr. Reddy’s Lab has a dividend yield of 0.62 percent.
Dr. Reddy’s Laboratories Limited is engaged through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products – offering a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), generics, biosimilars, and differentiated formulations.
Dr. Reddy’s Lab reported a significant growth in revenue from operations, experiencing a year-on-year rise of nearly 20 percent, from Rs. 7,114 crores in Q4 FY24 to Rs. 8,528 crores in Q4 FY25.
Similarly, the company’s net profit increased during the same period from Rs. 1,310 crores to Rs. 1,587 crores, representing a significant rise of nearly 21 percent YoY.
The company’s revenue from operations grew at a 3-year CAGR of around 15 percent between FY22 and FY25, while the net profit grew by about 38 percent CAGR over the same period.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
